Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049764 · ClinicalTrials.gov registry record · Phase 3
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 474
- Enrollment target
NCT00049764 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 474 participants.
The verdict
NCT00049764, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 474 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated). 2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with severe sepsis. 3. The side effects that might be associated with drotrecogin alfa (activated) administration to children with severe sepsis.
Interventions
- DRUG Placebo
- DRUG Drotrecogin alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049764
The ClinicalTrials.gov registry entry for NCT00049764 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00049764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049764 about?
NCT00049764 is a clinical study titled "Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis". The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated). 2. Whether drotrecogin alfa (activated) minimizes long term disa...
What is the current status of trial NCT00049764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 474 participants. The study started on 2002-11. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00049764?
The interventions under investigation include: Placebo (DRUG), Drotrecogin alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00049764?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.